OOIR: Observatory of International Research

Papers

(The H4-Index of Prostate Cancer and Prostatic Diseases is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer	116
Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level	91
A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk	65
Advances in PSMA-targeted therapy for prostate cancer	64
Racial disparities in prostate cancer among black men: epidemiology and outcomes	53
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	51
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies	49
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men	45
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors	42
Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis	41
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide	40
Quality of information and appropriateness of ChatGPT outputs for urology patients	38
3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction	36
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	36
Treating the patient and not just the cancer: therapeutic burden in prostate cancer	35
Clinical considerations for the management of androgen indifferent prostate cancer	32
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and networ	32
Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth	31
Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study	31
Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis	30
The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis	30
Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis	30
Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review	28
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients	27
The microbiome and prostate cancer	26

Robotic assisted simple prostatectomy versus other treatment modalities for large benign prostatic hyperplasia: a systematic review and meta-analysis of over 6500 cases	25
Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study	25
Disparities in germline testing among racial minorities with prostate cancer	25